GlassScriptPhysician profile
Lanelle S Williams
NPI 1508855537
$2,935.35
in general payments reported to CMS, 2019-2025
26 companies · $514 in 2025
The $514 reported for 2025 was more than what 78% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $327 · 2020: $61.05 · 2021: $240 · 2022: $978 · 2023: $350 · 2024: $465 · 2025: $514.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,275 · Education: $55.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,274.51 |
| Education | $55.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $357.76 | 2019-2025 | Tecnis Iol, Tecnis Iol |
| Sun Pharmaceutical Industries INC. | $276.89 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $252.69 | 2022-2025 | Miebo, Xiidra, Envista Mx60 Iol |
| Biotissue Holdings INC. | $244.16 | 2019-2025 | |
| Abbvie INC. | $176.02 | 2022-2025 | Vuity, Lumigan, Alphagan P |
| Tarsus Pharmaceuticals, INC. | $170.93 | 2024-2025 | Xdemvy |
| Alcon Vision LLC | $151.98 | 2022-2025 | Tryptyr |
| New World Medical,INC. | $134.52 | 2022-2023 | |
| Glaukos Corporation | $132.05 | 2022-2024 | Radius |
| Horizon Therapeutics Plc | $124.99 | 2022 | |
| Kala Pharmaceuticals, INC. | $115.18 | 2021 | |
| Rxsight INC | $113.01 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Oyster Point Pharma, INC. | $111.52 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $97.04 | 2019-2022 | |
| Thea Pharma INC. | $83.88 | 2023-2024 | Iyuzeh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $77.71 | 2019-2021 | |
| Spark Therapeutics, INC. | $50.31 | 2021-2022 | |
| Dompe US, INC. | $47.82 | 2021-2024 | Oxervate |
| Novartis Pharmaceuticals Corporation | $39.23 | 2019-2022 | |
| Amgen INC. | $33.78 | 2024 | Tepezza |
| Sight Sciences, INC. | $27.77 | 2019-2022 | |
| Shire North American Group INC | $25.94 | 2019 | |
| Harrow Eye, LLC | $24.89 | 2025 | Vevye |
| Ortho-Clinical Diagnostics, INC. | $23.47 | 2025 | Inflammadry |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.72 | 2019 | |
| Maculogix, INC. | $20.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanelle Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.